zanamivir has been researched along with laninamivir in 97 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (3.09) | 29.6817 |
| 2010's | 85 (87.63) | 24.3611 |
| 2020's | 9 (9.28) | 2.80 |
| Authors | Studies |
|---|---|
| Kakuta, M; Kubo, S; Nasu, H; Tokumitsu, A; Tomozawa, T; Yamashita, M | 1 |
| Arai, M; Honda, T; Kobayashi, Y; Kubo, S; Masuda, T; Yamashita, M | 1 |
| Kakuta, M; Kubo, S; Tokumitsu, A; Tomozawa, T; Yamashita, M | 2 |
| Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Sheu, TG | 1 |
| Abdel-Mageed, WM; Bayoumi, SA; Chen, C; Dai, H; Gao, GF; Li, L; Liu, L; Liu, X; Lv, Y; Malik, A; Sayed, HM; Song, F; Vavricka, CJ; Wang, L; Zhang, J; Zhang, L | 1 |
| Aljohani, MA; Keil, JM; Rafn, GR; Sahebjam-Atabaki, R; Sun, XL; Turan, IM | 1 |
| Koyama, K; Miura, S; Nakai, N; Oitate, M; Okazaki, O; Takahashi, M; Takakusa, H | 1 |
| Ishizuka, H; Okabe, H; Yoshiba, S; Yoshihara, K | 2 |
| Hoshi, M; Kobayashi, N; Koyama, K; Murai, T; Nakai, N; Okazaki, O; Takahashi, M; Takakusa, H; Yamamura, N | 1 |
| Kawaoka, Y; Kiso, M; Kubo, S; Le, QM; Nidom, CA; Ozawa, M; Yamashita, M | 1 |
| Reece, PA | 1 |
| Chang, SC; Chu, DW; Kim, MJ; Ohashi, Y; Watanabe, A | 1 |
| Yamashita, M | 1 |
| Deyde, VM; Fry, AM; Garten, RJ; Gubareva, LV; Klimov, AI; Mishin, VP; Nguyen, HT; Okomo-Adhiambo, M; Shaw, MW; Sheu, TG; Sleeman, K; Trujillo, AA | 1 |
| Li, MS; Mai, BK | 1 |
| Ikematsu, H; Kawai, N | 1 |
| Feng, E; Gao, F; Gao, GF; He, J; Jiang, H; Li, Q; Liu, H; Liu, J; Liu, Y; Qi, J; Vavricka, CJ; Wang, J; Wang, M; Wu, Y | 1 |
| Gill, P; Harnden, A; Perera, R; Shun-Shin, M; Wang, K | 2 |
| Cash, HL; Fujita, J; Higa, F; Sunagawa, S; Tateyama, M; Uno, T | 1 |
| Furuie, H; Ishizuka, H; Okabe, H; Toyama, K; Yoshiba, S | 1 |
| Ito, H; Katsumi, Y; Kidowaki, S; Matsui, F; Mibayashi, A; Otabe, O; Tsuma, Y | 1 |
| Kashiwagi, S; Mitsui, N; Niwa, S; Shiosakai, K; Shiozawa, T; Tanigawa, M; Yamaguchi, F; Yamaguchi, H; Yamanouchi, N; Yoshida, S | 1 |
| Fukushi, M; Kubo, S; Kudo, K; Miyoshi-Akiyama, T; Yamamoto, K; Yamashita, M | 1 |
| Watanabe, A | 1 |
| Hannongbua, S; Kamlungsua, K; Khuntawee, W; Meeprasert, A; Nunthaboot, N; Rungrotmongkol, T | 1 |
| Kashiwagi, S; Mitsui, N; Shiosakai, K; Shiozawa, T; Tanigawa, M; Yamaguchi, F; Yamaguchi, H; Yamanouchi, N; Yoshida, S | 1 |
| Imai, T; Izumi, T; Kobayashi, N; Koyama, K; Nakai, D; Nakai, N; Takahashi, M | 1 |
| Sato, R | 1 |
| Fujisaki, S; Imai, M; Kishida, N; Odagiri, T; Sato, H; Takashita, E; Taniwaki, T; Tashiro, M; Xu, H; Yokoyama, M | 2 |
| Eda, H; Fukushima, M; Nakano, T; Niwa, S; Okumura, A; Tanabe, T; Tsutsumi, H; Yonemochi, R | 1 |
| Ishizuka, H; Kubo, Y; Yoshihara, K | 1 |
| Gubareva, LV; Klimov, AI; Li, Y; Lysén, C; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K; Xu, X | 1 |
| Awamura, S; Ikematsu, H; Ishida, K; Kashiwagi, S; Okamoto, T; Uemori, M; Watanabe, A | 1 |
| Baranovich, T; Dapat, C; Dapat, IC; Kondo, H; Saito, K; Saito, R; Shobugawa, Y; Suzuki, H; Suzuki, Y | 1 |
| Ariga, T; Ishiguro, N; Kaiho, M; Kikuta, H; Koseki, N; Oba, K; Togashi, T | 1 |
| Kakuta, M; Kubo, S; Tanaka, M; Tobiume, S; Tomozawa, T; Yamashita, M | 1 |
| Gubareva, LV; Guo, Z; Levine, M; Mishin, VP; Nguyen, HT; Okomo-Adhiambo, M; Sleeman, K; Stevens, J; Tamura, D; Xu, X; Yang, H | 1 |
| Farrukee, R; Hurt, AC; Mosse, J | 1 |
| Balish, A; Fry, AM; Garten, RJ; Gubareva, LV; Guo, Z; Mishin, VP; Sleeman, K; Stevens, J; Villanueva, J | 1 |
| Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N | 6 |
| Izumi, T; Koyama, K; Kubota, K; Munemasa, T; Nakai, D; Ogura, Y; Oofune, Y; Shinagawa, A; Watanabe, M | 1 |
| Kanda, T; Mizuno, S; Mizuno, T | 1 |
| Barr, IG; Hurt, AC; Kelso, A; Kwok, S; Leang, SK; Maurer-Stroh, S; Sullivan, SG | 1 |
| Asai, T; Ichikawa, M; Ikezoe, I; Matsumoto, J; Miyagawa, S; Takemoto, Y; Yano, T | 1 |
| Bamba, M; Ichikawa, M; Ide, Y; Kawakami, C; Kawaoka, Y; Mitamura, K; Sakai-Tagawa, Y; Sugaya, N; Yamaguchi, Y; Yamazaki, M; Yasuhara, R | 1 |
| Abed, Y; Boivin, G; Desrochers, FM; Hamilton, S; Luttick, A; Pryor, MJ; Samson, M; Tucker, SP | 1 |
| Besselaar, T; Correia, V; Daniels, RS; Drager-Dayal, R; Fry, A; Gregory, V; Gubareva, L; Hurt, AC; Kageyama, T; Lackenby, A; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Tashiro, M; Wang, D; Wong, S; Zhang, W | 1 |
| Kubo, T; Minakami, H; Nakai, A; Saito, S; Unno, N | 1 |
| Ali, Z; Dapat, C; Dapat, IC; Dbaibo, G; Ghanem, S; Kayali, G; Kondo, H; Lteif, M; Saito, K; Saito, R; Suzuki, H; Zaraket, H | 1 |
| Li, Y; Ma, D; Tian, J; Zhong, J | 1 |
| Barrett, S; McKimm-Breschkin, JL | 1 |
| Ison, MG | 1 |
| Besselaar, T; Daniels, RS; Fry, A; Gregory, V; Gubareva, L; Huang, W; Hurt, AC; Lackenby, A; Leang, SK; Lo, J; Mak, GC; Meijer, A; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Tashiro, M; Wang, D; Zhang, W | 1 |
| Campbell, AP; DeBiasi, RL; Fry, AM; Gubareva, LV; Loechelt, B; Mishin, VP; Okomo-Adhiambo, M; Tamura, D; Wiedermann, BL | 1 |
| Hurt, AC; Margo, K; Morton, DA; Mosse, J; Oh, DY; Panozzo, J; Piedrafita, D | 1 |
| Azuma, T; Inoyama, T; Ishiuchi, H; Mino, Y; Sato, T; Tanaka, H; Teranishi, Y; Yamaoka, M; Yamashita, N | 1 |
| Batool, S; Kamal, MA; Kamal, W; Mushtaq, G | 1 |
| Cheong, HJ; Choi, WS; Kim, WJ; Noh, JY; Song, JY | 1 |
| Abed, Y; Ann, J; Beaulieu, E; Boivin, G; Bouhy, X; Carbonneau, J; Dubé, K; Hamelin, ME; Joly, MH; Mallett, C | 1 |
| Dapat, C; Fujii, K; Hassan, MR; Hibino, A; Kondo, H; Okazaki, M; Otsuka, T; Saito, R; Shobugawa, Y; Yagami, R | 1 |
| Haraki, M; Hishiki, H; Inoue, N; Ishiwada, N; Kameoka, Y; Kurosaki, T; Nagasawa, K; Naito, S; Someya, T; Suzuki, K | 1 |
| Awamura, S; Ikematsu, H; Kashiwagi, S; Uemori, M; Watanabe, A | 1 |
| Kitazawa, T; Koga, I; Ota, Y; Seo, K; Yoshino, Y | 1 |
| Azuma, T; Hisamatsu, K; Hosomaru, K; Ishida, M; Kunitou, M; Mikata, S; Mino, Y; Otomo, K; Shimizu, M; Yunoki, A | 1 |
| Ishiwada, N; Isobe, K; Nakano, T; Sumitani, T; Uemori, M | 1 |
| Besselaar, TG; Daniels, RS; Fry, A; Gregory, V; Gubareva, LV; Huang, W; Hurt, AC; Jorquera, PA; Lackenby, A; Leang, SK; Lo, J; Meijer, A; Odagiri, T; Pereyaslov, D; Rebelo-de-Andrade, H; Siqueira, MM; Takashita, E; Wang, D; Zhang, W | 1 |
| Fujii, T; Higashiguchi, M; Matsumoto, T | 1 |
| Baranovich, T; Davis, CT; Gubareva, LV; Guo, Z; Hodges, E; Sleeman, K; Stevens, J; Yang, H | 1 |
| Furuie, H; Ishizuka, H; Toyama, K | 1 |
| Hasegawa, H; Ito, M; Kawaoka, Y; Kiso, M; Lopes, TJS; Nakajima, N; Neumann, G; Yamashita, M; Yamayoshi, S | 1 |
| Hasegawa, T; Hirotsu, N; Saisho, Y; Shishido, T | 1 |
| Akutsu, Y; Aoyagi, H; Ariga, T; Arioka, H; Azuma, K; Furuyama, H; Hatae, Y; Hazama, K; Inagawa, A; Ishiguro, N; Ishizaka, A; Kaiho, M; Kawamura, N; Kikuta, H; Koike, A; Konno, M; Koseki, N; Kumita, Y; Matsuzono, Y; Morita, K; Murashita, M; Nagano, N; Oba, K; Odagawa, Y; Okamura, A; Sawada, Y; Shibata, M; Shida, S; Tabata, Y; Takada, K; Tobise, C; Togashi, T; Tsubakihara, K; Tsuchida, A; Tsuchiyama, A; Uetsuji, K; Watanabe, T; Yamanaka, T; Yamazaki, S; Yasoshima, K; Yasuda, K; Yoshioka, M | 1 |
| Fushimi, K; Matsui, H; Michihata, N; Miyairi, I; Morisaki, N; Okubo, Y; Shoji, K; Uda, K; Yasunaga, H | 1 |
| Ikematsu, H; Ishikawa, Y; Iwaki, N; Kashiwagi, S; Kawai, N; Shiosakai, K; Yamaguchi, H | 1 |
| Asai, K; Fujioka, M; Hirata, K; Kimura, T; Kureya, Y; Shinataku, H; Tocino, Y; Yoshi, N | 1 |
| Miyazaki, C; Momoi, M; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
| Hoshino, K; Kubo, S; Tomozawa, T; Yamashita, M | 1 |
| Arinaga-Hino, T; Hirai, S; Ide, T; Kawaguchi, T; Nagamatsu, H; Shimizu, M; Takata, A; Tanikawa, K; Tateishi, H; Tokushige, T; Torimura, T | 1 |
| Butler, J; Farrukee, R; Hurt, AC; Reading, PC | 1 |
| Betsuyaku, T; Ogawa, T; Ohgino, K; Omori, N; Sayama, K; Tanaka, K | 1 |
| Han, N; Kim, IW; Oh, JM | 1 |
| Miyazaki, C; Momoi, MY; Ohkusa, Y; Okabe, N; Sugawara, T; Taniguchi, K | 1 |
| Adams, SE; Bovin, NV; Donnelly, RP; Ilyushina, NA; Kan, A; Lugovtsev, VY | 1 |
| Akimoto, M; Fujisaki, S; Hasegawa, H; Kaido, T; Kishida, N; Kuwahara, T; Miura, H; Morita, H; Nagata, S; Nakamura, K; Sato, A; Shirakura, M; Sugawara, H; Takashita, E; Watanabe, S; Yasui, Y | 1 |
| Chiba, T; Chikada, S; Matsuoka, Y; Nakano, T; Shiosakai, K; Yamaguchi, H | 1 |
| Bando, T; Chong, Y; Ikematsu, H; Iwaki, N; Kashiwagi, S; Kawai, N; Shindo, S; Takasaki, Y; Tani, N | 1 |
| Aoki, S; Chon, I; Kakuya, F; Kawashima, T; Kitano, A; Kodo, N; Li, J; Minato, M; Nagata, N; Ono, Y; Phyu, WW; Saito, R; Saito, T; Sato, I; Shimada, Y; Sun, Y; Suzuki, E; Tanaka, T; Wagatsuma, K; Watanabe, H | 1 |
| Kumar, R; Sagar, R; Tyagi, R; Yadav, Y | 1 |
13 review(s) available for zanamivir and laninamivir
| Article | Year |
|---|---|
Sialidase Inhibitors with Different Mechanisms.
Topics: Antiviral Agents; Biological Products; Enzyme Inhibitors; Humans; N-Acetylneuraminic Acid; Neuraminidase; Oseltamivir; Sialic Acids; Zanamivir | 2022 |
Treatment options for H5N1: lessons learned from the H1N1 pandemic.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H5N1 Subtype; Influenza, Human; Oseltamivir; Pneumonia, Viral; Pyrans; Severity of Illness Index; Sialic Acids; Zanamivir | 2010 |
Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Guanidines; Humans; Influenza, Human; Mice; Neuraminidase; Orthomyxoviridae; Oseltamivir; Pandemics; Prodrugs; Pyrans; Rats; Sialic Acids; Zanamivir | 2010 |
Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
Topics: Administration, Inhalation; Adult; Animals; Antiviral Agents; Birds; Caprylates; Child; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza in Birds; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Viral Proteins; Virus Replication; Zanamivir | 2011 |
Neuraminidase inhibitors for preventing and treating influenza in children.
Topics: Acetamides; Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2012 |
Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).
Topics: Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Guanidines; Humans; Infant; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Randomized Controlled Trials as Topic; Sialic Acids; Zanamivir | 2012 |
Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance.
Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Gastrointestinal Diseases; Guanidines; Humans; Japan; Mental Disorders; Nervous System Diseases; Product Surveillance, Postmarketing; Pyrans; Sialic Acids; Zanamivir | 2012 |
[Drug resistance of influenza viruses].
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A virus; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Matrix Proteins; Zanamivir | 2012 |
Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses.
Topics: Antiviral Agents; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2013 |
Optimizing antiviral therapy for influenza: understanding the evidence.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; RNA-Dependent RNA Polymerase; Sialic Acids; Viral Matrix Proteins; Viral Proteins; Zanamivir | 2015 |
Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives.
Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Clinical Trials as Topic; Cyclopentanes; Drug Resistance, Viral; Guanidines; Hospitalization; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Oseltamivir; Pyrans; Pyrazines; Republic of Korea; Sialic Acids; Zanamivir | 2015 |
A meta-analysis of laninamivir octanoate for treatment and prophylaxis of influenza.
Topics: Administration, Inhalation; Antiviral Agents; Betainfluenzavirus; Disease Management; Drug Therapy, Combination; Guanidines; Humans; Influenza A virus; Influenza, Human; Post-Exposure Prophylaxis; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2018 |
Conformationally locked sugar derivatives and analogues as potential neuraminidase inhibitors.
Topics: Antiviral Agents; Cyclohexenes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Neuraminidase; Orthomyxoviridae; Oseltamivir; Zanamivir | 2023 |
15 trial(s) available for zanamivir and laninamivir
| Article | Year |
|---|---|
Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.
Topics: Administration, Inhalation; Adult; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Guanidines; Half-Life; Humans; Male; Middle Aged; Neuraminidase; Prodrugs; Pyrans; Sialic Acids; Young Adult; Zanamivir | 2010 |
Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Area Under Curve; Enzyme Inhibitors; Female; Guanidines; Half-Life; Humans; Male; Middle Aged; Neuraminidase; Prodrugs; Pyrans; Renal Insufficiency; Severity of Illness Index; Sialic Acids; Zanamivir | 2011 |
Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Zanamivir | 2010 |
Effect of a single inhalation of laninamivir octanoate in children with influenza.
Topics: Administration, Inhalation; Adolescent; Child; Child, Preschool; Female; Fever; Guanidines; Humans; Influenza, Human; Male; Neuraminidase; Pyrans; Sialic Acids; Surveys and Questionnaires; Treatment Outcome; Zanamivir | 2012 |
A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.
Topics: Adult; Aged; Antiviral Agents; Asthma; Chronic Disease; Double-Blind Method; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2013 |
Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.
Topics: Administration, Inhalation; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Disease Transmission, Infectious; Double-Blind Method; Family Characteristics; Female; Guanidines; Humans; Infant; Influenza, Human; Male; Middle Aged; Placebos; Post-Exposure Prophylaxis; Pyrans; Sialic Acids; Zanamivir | 2013 |
The duration of fever and other symptoms after the initiation of laninamivir octanoate hydrate in the Japanese 2011-2012 influenza season.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Fever; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Pyrans; Sialic Acids; Young Adult; Zanamivir | 2014 |
Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.
Topics: Acids, Carbocyclic; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Outpatients; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Young Adult; Zanamivir | 2013 |
Continued effectiveness of laninamivir octanate hydrate for influenza treatment in Japan: comparison between the 2011-2012 and 2012-2013 influenza seasons.
Topics: Antiviral Agents; Child; Disease Outbreaks; Female; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Male; Microbial Sensitivity Tests; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2014 |
Clinical outcome of laninamivir octanoate hydrate for influenza in the 2013-2014 Japanese season.
Topics: Antiviral Agents; Child; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Inhibitory Concentration 50; Male; Pyrans; Sialic Acids; Zanamivir | 2015 |
Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
Topics: Administration, Inhalation; Adolescent; Adult; Antiviral Agents; Child; Double-Blind Method; Enzyme Inhibitors; Family Characteristics; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Post-Exposure Prophylaxis; Pyrans; Sialic Acids; Young Adult; Zanamivir | 2016 |
Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Female; Guanidines; Humans; Influenza, Human; Japan; Male; Middle Aged; Oseltamivir; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2017 |
Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children.
Topics: Administration, Inhalation; Age Factors; Antiviral Agents; Child; Child, Preschool; Communicable Disease Control; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Family Characteristics; Follow-Up Studies; Guanidines; Humans; Influenza, Human; Japan; Monitoring, Physiologic; Pyrans; Risk Assessment; Sialic Acids; Treatment Outcome; Zanamivir | 2016 |
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Antiviral Agents; Child; Enzyme Inhibitors; Female; Fever; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Pregnancy; Product Surveillance, Postmarketing; Pyrans; Sialic Acids; Treatment Outcome; Young Adult; Zanamivir | 2017 |
Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4-12 years): an open-label, randomized study in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Female; Guanidines; Humans; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir | 2018 |
69 other study(ies) available for zanamivir and laninamivir
| Article | Year |
|---|---|
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; HeLa Cells; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Mice; Neuraminidase; Prodrugs; Zanamivir | 2009 |
Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.
Topics: Administration, Intranasal; Alphainfluenzavirus; Animals; Antiviral Agents; Betainfluenzavirus; Esters; Mice; Neuraminidase; Prodrugs; Zanamivir | 2009 |
Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Ferrets; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Treatment Outcome; Zanamivir | 2010 |
Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.
Topics: Acids, Carbocyclic; Animals; Cell Line; Cyclopentanes; Dogs; Enzyme Assays; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Zanamivir | 2010 |
Benzophenone C-glucosides and gallotannins from mango tree stem bark with broad-spectrum anti-viral activity.
Topics: 3C Viral Proteases; Antineoplastic Agents, Phytogenic; Antiviral Agents; Benzophenones; Cell Proliferation; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enterovirus B, Human; HeLa Cells; Hep G2 Cells; Humans; Hydrolyzable Tannins; Influenza A virus; Mangifera; Molecular Structure; Plant Bark; Plant Stems; Protease Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Viral Proteins | 2014 |
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
Topics: Animals; Antiviral Agents; Autoradiography; Enzyme Inhibitors; Esterases; Female; Guanidines; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae; Prodrugs; Pyrans; Sialic Acids; Trachea; Zanamivir | 2009 |
Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.
Topics: Animals; Antiviral Agents; Bile; Chromatography, Thin Layer; Enzyme Inhibitors; Feces; Guanidines; Male; Neuraminidase; Prodrugs; Pyrans; Radioactivity; Rats; Rats, Sprague-Dawley; Sialic Acids; Time Factors; Tissue Distribution; Tissue Extracts; Zanamivir | 2010 |
Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Topics: Animals; Antiviral Agents; Female; Guanidines; Influenza A Virus, H5N1 Subtype; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Zanamivir | 2010 |
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Topics: Acids, Carbocyclic; Adamantane; Amino Acid Substitution; Animals; Antiviral Agents; Cell Line; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Pyrrolidines; Sialic Acids; Viral Plaque Assay; Zanamivir | 2010 |
Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
Topics: Antiviral Agents; Drug Design; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H5N1 Subtype; Molecular Dynamics Simulation; Mutation; Neuraminidase; Pyrans; Sialic Acids; Zanamivir | 2011 |
High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.
Topics: Administration, Intranasal; Animals; Antiviral Agents; Cell Line; Dogs; Drug Resistance, Viral; Female; Guanidines; Influenza A virus; Inhibitory Concentration 50; Lung; Mice; Mice, Inbred BALB C; Mutation; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Zanamivir | 2012 |
Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
Topics: Antiviral Agents; Caprylates; Catalytic Domain; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Prodrugs; Pyrans; Sialic Acids; Zanamivir | 2011 |
Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics.
Topics: Administration, Inhalation; Antiviral Agents; Epidemics; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Japan; Neuraminidase; Pyrans; Sialic Acids; Zanamivir | 2013 |
Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.
Topics: Administration, Inhalation; Adult; Antiviral Agents; Guanidines; Humans; Male; Middle Aged; Neuraminidase; Prodrugs; Pyrans; Sialic Acids; Young Adult; Zanamivir | 2012 |
Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 Virus.
Topics: Animals; Body Weight; Carbon Dioxide; Chemokines; Dogs; Drug Therapy, Combination; Female; Guanidines; Influenza A Virus, H1N1 Subtype; Lung; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Organ Size; Orthomyxoviridae Infections; Oxygen; Pressure; Pulmonary Surfactant-Associated Protein D; Pulmonary Surfactants; Pyrans; Sialic Acids; Survival Analysis; Viral Load; Zanamivir | 2012 |
Binding pattern of the long acting neuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 and pandemic H1N1.
Topics: Antiviral Agents; Catalytic Domain; Enzyme Inhibitors; Guanidines; Humans; Hydrogen Bonding; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Molecular Docking Simulation; Mutation; Neuraminidase; Oseltamivir; Protein Binding; Protein Interaction Domains and Motifs; Pyrans; Sialic Acids; Static Electricity; Viral Proteins; Zanamivir | 2012 |
Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Child; Female; Fever; Guanidines; Humans; Influenza, Human; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neuraminidase; Product Surveillance, Postmarketing; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2013 |
Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
Topics: Administration, Intranasal; Animals; Autoradiography; Cells, Cultured; Enzyme Inhibitors; Guanidines; Lung; Mice; Mice, Inbred BALB C; Neuraminidase; Prodrugs; Pyrans; Sialic Acids; Trachea; Zanamivir | 2013 |
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Catalytic Domain; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; HEK293 Cells; Humans; Influenza B virus; Madin Darby Canine Kidney Cells; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Protein Conformation; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2012 |
Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antiviral Agents; Child; Delirium; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Pyrans; Sialic Acids; Syncope; Zanamivir | 2013 |
Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.
Topics: Animals; Antiviral Agents; Catalytic Domain; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza B virus; Influenza, Human; Japan; Madin Darby Canine Kidney Cells; Models, Molecular; Mutation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2013 |
Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza, Human; Male; Middle Aged; Neuraminidase; Prodrugs; Pyrans; Sialic Acids; Zanamivir | 2013 |
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Topics: Acids, Carbocyclic; Africa; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Neuraminidase; Oceania; Oseltamivir; Pyrans; Seasons; Sentinel Surveillance; Sialic Acids; South America; Zanamivir | 2013 |
Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Microbial Sensitivity Tests; Neuraminidase; Pandemics; Pyrans; Seasons; Sialic Acids; Viral Proteins; Zanamivir | 2013 |
Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Chromatography, Affinity; Female; Fever; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Male; Prospective Studies; Pyrans; Sialic Acids; Time Factors; Treatment Outcome; Zanamivir | 2014 |
Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
Topics: Administration, Intravenous; Animals; Antiviral Agents; Disease Models, Animal; Female; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Mice; Mice, Inbred BALB C; Pyrans; Sialic Acids; Zanamivir | 2013 |
Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cell Culture Techniques; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Gene Expression; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Load; Viral Proteins; Virus Replication; Zanamivir | 2013 |
Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.
Topics: Acids, Carbocyclic; Animals; Antiviral Agents; Cyclopentanes; Dogs; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Madin Darby Canine Kidney Cells; Oseltamivir; Pyrans; Sialic Acids; United States; Virus Replication; Zanamivir | 2014 |
Identification of bioactivating enzymes involved in the hydrolysis of laninamivir octanoate, a long-acting neuraminidase inhibitor, in human pulmonary tissue.
Topics: Administration, Inhalation; Aged; Guanidines; Humans; Hydrolysis; Lung; Male; Middle Aged; Neuraminidase; Pyrans; Sialic Acids; Zanamivir | 2014 |
Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Guanidines; Humans; Influenza Vaccines; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Orthomyxoviridae; Pyrans; Sialic Acids; Vaccination; Young Adult; Zanamivir | 2014 |
Peramivir and laninamivir susceptibility of circulating influenza A and B viruses.
Topics: Acids, Carbocyclic; Africa; Antiviral Agents; Asia; Cyclopentanes; Guanidines; Humans; Influenza A virus; Influenza B virus; Influenza, Human; Japan; Microbial Sensitivity Tests; Mutation, Missense; Neuraminidase; Oceania; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2014 |
Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Fever; Guanidines; Humans; Infant; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Neuraminidase; Oseltamivir; Pyrans; Severity of Illness Index; Sialic Acids; Time Factors; Treatment Outcome; Viral Proteins; Virus Shedding; Zanamivir | 2015 |
Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
Topics: Antiviral Agents; Drug Resistance, Viral; Guanidines; Hemagglutination Tests; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Microbial Sensitivity Tests; Neuraminidase; Pyrans; Sialic Acids; Viral Plaque Assay; Zanamivir | 2014 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A virus; Influenza, Human; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2014 |
Pregnancy outcomes of women exposed to laninamivir during pregnancy.
Topics: Adolescent; Adult; Antiviral Agents; Female; Guanidines; Humans; Infant, Newborn; Influenza, Human; Japan; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyrans; Retrospective Studies; Sialic Acids; Young Adult; Zanamivir | 2014 |
Characterization of human Influenza Viruses in Lebanon during 2010-2011 and 2011-2012 post-pandemic seasons.
Topics: Acids, Carbocyclic; Amantadine; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Lebanon; Microbial Sensitivity Tests; Mutation; Neuraminidase; Oseltamivir; Pandemics; Phylogeny; Pyrans; Sialic Acids; Zanamivir | 2014 |
Organocatalytic and scalable synthesis of the anti-influenza drugs zanamivir, laninamivir, and CS-8958.
Topics: Antiviral Agents; Catalysis; Guanidines; Humans; Influenza, Human; Pyrans; Sialic Acids; Zanamivir | 2014 |
Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.
Topics: Animals; Antiviral Agents; Dogs; Drug Resistance, Viral; Guanidines; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Inhibitory Concentration 50; Madin Darby Canine Kidney Cells; Mutation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2015 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; China; Cyclopentanes; Disease Outbreaks; Drug Resistance, Viral; Enzyme Inhibitors; Europe; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Inhibitory Concentration 50; Japan; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Phylogeny; Pyrans; Sialic Acids; Time Factors; United States; World Health Organization; Zanamivir | 2015 |
Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Immunocompromised Host; Infant; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Mutation, Missense; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Viral Proteins; Zanamivir | 2015 |
Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
Topics: Administration, Inhalation; Animals; Antiviral Agents; Disease Models, Animal; Drug Carriers; Ferrets; Guanidines; Orthomyxoviridae Infections; Placebos; Powders; Pyrans; Sialic Acids; Zanamivir | 2015 |
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Young Adult; Zanamivir | 2015 |
Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan.
Topics: Acids, Carbocyclic; Antiviral Agents; Cities; Cyclopentanes; Drug Residues; Environmental Monitoring; Guanidines; Japan; Limit of Detection; Oseltamivir; Ozone; Pyrans; Risk Assessment; Rivers; Sewage; Sialic Acids; Water Pollutants, Chemical; Water Purification; Zanamivir | 2015 |
Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.
Topics: Acids, Carbocyclic; Binding Sites; Cyclopentanes; Databases, Chemical; Glycoside Hydrolase Inhibitors; Guanidines; Influenza A Virus, H5N1 Subtype; Ligands; Molecular Docking Simulation; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Structure-Activity Relationship; Viral Proteins; Zanamivir | 2016 |
Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets.
Topics: Animals; Antiviral Agents; Drug Resistance, Viral; Ferrets; Gene Deletion; Genetic Fitness; Guanidines; Hemagglutinin Glycoproteins, Influenza Virus; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Mutation; Neuraminidase; Orthomyxoviridae Infections; Pyrans; RNA, Viral; Sialic Acids; Virus Replication; Zanamivir | 2016 |
Influenza Virus Shedding in Laninamivir-Treated Children upon Returning to School.
Topics: Antiviral Agents; Child; Demography; Female; Guanidines; Health; Humans; Influenza A Virus, H3N2 Subtype; Influenza, Human; Male; Neuraminidase; Pyrans; RNA, Viral; Schools; Sialic Acids; Virus Shedding; Zanamivir | 2016 |
[Comparison of the clinical effectiveness of three neuraminidase inhibitors for Japanese pediatric patients with influenza in the 2013/2014 season].
Topics: Antiviral Agents; Child; Enzyme Inhibitors; Guanidines; Humans; Influenza, Human; Japan; Medication Adherence; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Time Factors; Zanamivir | 2015 |
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011-2012 to 2014-2015.
Topics: Administration, Inhalation; Antiviral Agents; Child; Female; Fever; Guanidines; Humans; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza, Human; Japan; Kaplan-Meier Estimate; Male; Product Surveillance, Postmarketing; Proportional Hazards Models; Pyrans; Sialic Acids; Treatment Outcome; Zanamivir | 2016 |
Fate of new three anti-influenza drugs and one prodrug in the water environment.
Topics: Acids, Carbocyclic; Amides; Antiviral Agents; Biodegradation, Environmental; Cyclopentanes; Environmental Monitoring; Fresh Water; Guanidines; Half-Life; Humans; Influenza, Human; Japan; Prodrugs; Pyrans; Pyrazines; Rivers; Seasons; Sewage; Sialic Acids; Water Pollutants, Chemical; Zanamivir | 2017 |
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Enzyme Inhibitors; Epidemiological Monitoring; Global Health; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza B virus; Influenza, Human; Inhibitory Concentration 50; Microbial Sensitivity Tests; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; World Health Organization; Zanamivir | 2017 |
Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
Topics: Acids, Carbocyclic; Antiviral Agents; Cyclopentanes; Databases, Genetic; Drug Resistance, Multiple, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H7N9 Subtype; Influenza, Human; Inhibitory Concentration 50; Neuraminidase; Oseltamivir; Protein Conformation; Pyrans; Recombinant Proteins; Sialic Acids; Viral Proteins; Zanamivir | 2017 |
Intrapulmonary Pharmacokinetics of Laninamivir, a Neuraminidase Inhibitor, after a Single Nebulized Administration of Laninamivir Octanoate in Healthy Japanese Subjects.
Topics: Administration, Inhalation; Adult; Antiviral Agents; Asian People; Bronchoalveolar Lavage Fluid; Dose-Response Relationship, Drug; Dry Powder Inhalers; Guanidines; Healthy Volunteers; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Neuraminidase; Pyrans; Sialic Acids; Viruses; Young Adult; Zanamivir | 2018 |
Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.
Topics: Amides; Animals; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Lung; Mice; Mice, Inbred BALB C; Mice, Nude; Neuraminidase; Nucleic Acid Synthesis Inhibitors; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Pyrazines; Sialic Acids; Zanamivir | 2018 |
Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan.
Topics: Acids, Carbocyclic; Adolescent; Betainfluenzavirus; Child; Child, Preschool; Cyclopentanes; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza A virus; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Seasons; Sialic Acids; Treatment Outcome; Zanamivir | 2018 |
Trends of neuraminidase inhibitors use in children with influenza related respiratory infections.
Topics: Acids, Carbocyclic; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Drug Utilization; Enzyme Inhibitors; Female; Guanidines; Hospitalization; Humans; Infant; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2018 |
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate in the 2016/17 Japanese influenza season; comparison with the 2011/12 to 2015/16 seasons.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Female; Fever; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Inhibitory Concentration 50; Male; Middle Aged; Pyrans; Seasons; Sialic Acids; Young Adult; Zanamivir | 2018 |
Comparison of the Clinical Courses of Patients with Influenza after Neuraminidase Inhibitors Treatment: A Postcard Survey of the 2013-2014 Influenza Season in Osaka.
Topics: Acids, Carbocyclic; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Cyclopentanes; Disease Outbreaks; Enzyme Inhibitors; Female; Guanidines; Humans; Infant; Influenza, Human; Japan; Male; Middle Aged; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Surveys and Questionnaires; Treatment Outcome; Zanamivir | 2016 |
Association of severe abnormal behavior and acetaminophen with/without neuraminidase inhibitors.
Topics: Acetaminophen; Adolescent; Age Factors; Antiviral Agents; Behavioral Symptoms; Child; Drug Therapy, Combination; Enzyme Inhibitors; Female; Guanidines; Humans; Incidence; Influenza, Human; Japan; Male; Neuraminidase; Oseltamivir; Pyrans; Risk Factors; Sialic Acids; Zanamivir | 2019 |
Efficacy of laninamivir octanoate in mice with advanced inflammation stage caused by infection of highly lethal influenza virus.
Topics: Animals; Antiviral Agents; Cell Line; Dogs; Enzyme Inhibitors; Female; Guanidines; Inflammation; Influenza A Virus, H5N1 Subtype; Influenza A Virus, H7N9 Subtype; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Neuraminidase; Orthomyxoviridae Infections; Oseltamivir; Pyrans; Sialic Acids; Zanamivir | 2019 |
Immune-mediated Drug-induced Liver Injury Caused by Laninamivir Octanoate Hydrate.
Topics: Adolescent; Antiviral Agents; Azathioprine; Chemical and Drug Induced Liver Injury; Female; Guanidines; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Influenza A virus; Influenza, Human; Jaundice; Pyrans; Sialic Acids; Zanamivir | 2019 |
Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Amino Acid Substitution; Animals; Antiviral Agents; Cyclopentanes; Dogs; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; HEK293 Cells; Humans; Influenza A Virus, H7N9 Subtype; Madin Darby Canine Kidney Cells; Neuraminidase; Oseltamivir; Pyrans; Serial Passage; Sialic Acids; Species Specificity; Viral Proteins; Zanamivir | 2019 |
Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases.
Topics: Administration, Inhalation; Adult; Antiviral Agents; Bronchoalveolar Lavage; Female; Glucocorticoids; Guanidines; Humans; Influenza A virus; Influenza, Human; Lung; Neuraminidase; Pneumonia; Pyrans; Respiration, Artificial; Sialic Acids; Tomography, X-Ray Computed; Treatment Outcome; Viral Proteins; Young Adult; Zanamivir | 2019 |
Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews.
Topics: Acids, Carbocyclic; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antiviral Agents; Child; Child, Preschool; Female; Guanidines; Humans; Infant; Infant, Newborn; Influenza, Human; Internet; Male; Middle Aged; Neuraminidase; Odds Ratio; Oseltamivir; Patient Participation; Pyrans; Risk Factors; Sialic Acids; United States; United States Food and Drug Administration; Young Adult; Zanamivir | 2020 |
Association of moderately abnormal behavior and administered neuraminidase inhibitors.
Topics: Acids, Carbocyclic; Adolescent; Antiviral Agents; Child; Cyclopentanes; Enzyme Inhibitors; Guanidines; Humans; Illness Behavior; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Pyrans; Sialic Acids; Young Adult; Zanamivir | 2020 |
Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone.
Topics: Antiviral Agents; Drug Resistance, Viral; Enzyme Inhibitors; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Interferons; Neuraminidase; Pyrans; Sialic Acids; Zanamivir | 2020 |
Detection of a Peramivir-Resistant Influenza B/Yamagata-Lineage Virus Imported from Indonesia in Aichi, Japan, March 2019.
Topics: Acids, Carbocyclic; Adult; Antiviral Agents; Dibenzothiepins; Drug Resistance, Viral; Guanidines; Humans; Indonesia; Influenza B virus; Influenza, Human; Japan; Male; Microbial Sensitivity Tests; Morpholines; Mutation; Neuraminidase; Pyrans; Pyridones; Sialic Acids; Triazines; Zanamivir | 2020 |
The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance.
Topics: Administration, Inhalation; Antiviral Agents; Child, Preschool; Guanidines; Humans; Influenza, Human; Neuraminidase; Product Surveillance, Postmarketing; Pyrans; Sialic Acids; Zanamivir | 2021 |
Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate: A study of the 2017/18 and 2018/19 seasons and comparison with the 2011/12 to 2016/17 Japanese influenza seasons.
Topics: Antiviral Agents; Fever; Guanidines; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza, Human; Japan; Neuraminidase; Pyrans; Seasons; Sialic Acids; Zanamivir | 2022 |
Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014-2019/2020 seasons in Japan: an o
Topics: Adult; Antiviral Agents; Child; Enzyme Inhibitors; Humans; Influenza, Human; Japan; Neuraminidase; Oseltamivir; Outpatients; RNA, Viral; Seasons; Zanamivir | 2023 |